Bill Text: TX HB4284 | 2021-2022 | 87th Legislature | Introduced
Bill Title: Relating to the creation of the opioid abatement account.
Spectrum: Partisan Bill (Republican 2-0)
Status: (Introduced - Dead) 2021-05-04 - Left pending in committee [HB4284 Detail]
Download: Texas-2021-HB4284-Introduced.html
By: Holland | H.B. No. 4284 |
|
||
|
||
relating to the creation of the opioid abatement account. | ||
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
SECTION 1. Subchapter G, Chapter 403, Government Code, is | ||
amended by adding Section 403.1044 to read as follows: | ||
Sec. 403.1044. OPIOID ABATEMENT ACCOUNT. (a) The opioid | ||
abatement account is a dedicated account in the general revenue | ||
fund. | ||
(b) The account is composed of: | ||
(1) money received by the state from any source | ||
resulting directly or indirectly from an action by the state | ||
against an opioid manufacturer, an opioid distributor, or another | ||
person in the opioid industry relating to a violation of state or | ||
federal law on the manufacture, marketing, distribution, or sale of | ||
opioids; | ||
(2) money appropriated or transferred to the account | ||
by the legislature; | ||
(3) gifts and grants contributed to the account; and | ||
(4) earnings on the principal of the account. | ||
(c) Money in the account may be appropriated only to a state | ||
agency for the abatement of opioid-related harms. | ||
(d) A state agency may use money appropriated to the agency | ||
from the account only to: | ||
(1) prevent opioid use disorder through | ||
evidence-based education and prevention, such as school-based | ||
prevention, early intervention, or health care services or programs | ||
intended to reduce the risk of opioid use by school-age children; | ||
(2) support efforts to prevent or reduce deaths from | ||
opioid overdoses or other opioid-related harms, including through | ||
increasing the availability or distribution of naloxone or other | ||
opioid antagonists for use by health care providers, first | ||
responders, persons experiencing an opioid overdose, families, | ||
schools, community-based service providers, social workers, or | ||
other members of the public; | ||
(3) create and provide training on the treatment of | ||
opioid addiction, including the treatment of opioid dependence with | ||
each medication approved for that purpose by the United States Food | ||
and Drug Administration, medical detoxification, relapse | ||
prevention, patient assessment, individual treatment planning, | ||
counseling, recovery supports, diversion control, and other best | ||
practices; | ||
(4) provide opioid use disorder treatment for youths | ||
and adults, with an emphasis on programs that provide a continuum of | ||
care that includes screening and assessment for opioid use disorder | ||
and co-occurring behavioral health disorders, early intervention, | ||
contingency management, cognitive behavioral therapy, case | ||
management, relapse management, counseling services, and | ||
medication-assisted treatments; | ||
(5) provide access to patients suffering from opioid | ||
dependence to all medications approved by the United States Food | ||
and Drug Administration for the treatment of opioid dependence and | ||
relapse prevention following opioid detoxification, including | ||
opioid agonists, partial agonists, and antagonists; and | ||
(6) support treatment alternatives that provide both | ||
psychosocial support and medication-assisted treatments in areas | ||
with geographical or transportation-related challenges, including | ||
providing access to mobile health services, and telemedicine, | ||
particularly in rural areas. | ||
SECTION 2. This Act takes effect September 1, 2021. |